NCT05897333Recruiting
Turkish Isolated Coronary Ectasia Registry: The T-ICE Registry
Turkish Isolated Coronary Ectasia Prospective Cohort Study: the T-ICE Registry
Source: ClinicalTrials.gov · Last updated 9 Jun 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The T-ICE study is a prospective, observational study aiming to have information about the treatment and long-term prognosis of patients with isolated coronary artery ectasia.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 22 Feb 2023
- Start date
- 15 Mar 2022
- Primary completion date
- 15 Mar 2032
- Lead sponsor
- Gazi University
- Diseases
- Coronary artery disease
- NCT number
- NCT05897333
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 15 Mar 2022 to the primary completion date, 15 Mar 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Life expectancy \<24 months
- Patients with ≥20% stenosis in a vessel ≥2 mm in diameter.
Who the study is looking for
- Isolated coronary artery ectasia (without ≥20% stenosis in any coronary artery ≥2 mm in diameter).
- All patients with isolated coronary ectasia with or without acute coronary syndrome will be included.
- Patients aged ≥18 years.
- Patients with discrete coronary artery aneurysm will be included.
Age in the registry: 18 years to 90 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gazi University, School of Medicine Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.